Patients’ perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases

Jeffrey J. Swigris*, Kevin K. Brown, Rayid Abdulqawi, Ketan Buch, Daniel F. Dilling, Dirk Koschel, Krishna Thavarajah, Rade Tomic, Yoshikazu Inoue

*Corresponding author for this work

Research output: Contribution to journalReview article

6 Scopus citations


The effects of interstitial lung disease (ILD) create a significant burden on patients, unsettling almost every domain of their lives, disrupting their physical and emotional well-being and impairing their quality of life (QoL). Because many ILDs are incurable, and there are limited reliably-effective, life-prolonging treatment options available, the focus of many therapeutic interventions has been on improving or maintaining how patients with ILD feel and function, and by extension, their QoL. Such patient-centred outcomes are best assessed by patients themselves through tools that capture their perceptions, which inherently incorporate their values and judgements. These patient-reported outcome measures (PROs) can be used to assess an array of constructs affected by a disease or the interventions implemented to treat it. Here, we review the impact of ILD that may present with a progressive-fibrosing phenotype on patients’ lives and examine how PROs have been used to measure that impact and the effectiveness of therapeutic interventions.

Original languageEnglish (US)
Article number180075
JournalEuropean Respiratory Review
Issue number150
StatePublished - 2018

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Patients’ perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases'. Together they form a unique fingerprint.

Cite this